EPHA2, a promising therapeutic target for hepatocellular carcinoma

被引：7
作者：
Wang, Hao
Qiu, Wei [1 ]
机构：
[1] Loyola Univ Chicago, Stritch Sch Med, Dept Surg, Maywood, IL 60153 USA
来源：
MOLECULAR & CELLULAR ONCOLOGY | 2021年 / 8卷 / 03期
基金：
美国国家卫生研究院;
关键词：
EPHA2; HCC; AKT; STAT3; JAK1; INHIBITION; RECEPTOR; LIGAND;
D O I：
10.1080/23723556.2021.1910009
中图分类号：
R73 [肿瘤学];
学科分类号：
100214 ;
摘要：
Identifying critical drivers of oncogenesis and tumor progression is essential for developing effective hepatocellular carcinoma (HCC) therapeutics. Our recent findings has demonstrated that targeting Ephrin Receptor A2 (EPHA2) suppresses HCC initiation and progression by dual inhibition of the Protein Kinase B (AKT) and Signal Transducer and Activator of Transcription 3 (STAT3) signaling.
引用
收藏
页数：3
相关论文
共 10 条
  • [1] Gene Expression Profiling of Muscle Stem Cells Identifies Novel Regulators of Postnatal Myogenesis
    Alonso-Martin, Sonia
    Rochat, Anne
    Mademtzoglou, Despoina
    Morais, Jessica
    de reynies, Aurelien
    Aurade, Frederic
    Chang, Ted Hung-Tse
    Zammit, Peter S.
    Relaix, Frederic
    [J]. FRONTIERS IN CELL AND DEVELOPMENTAL BIOLOGY, 2016, 4
  • [2] Genetic and pharmacologic inhibition of EPHA2 promotes apoptosis in NSCLC
    Arnato, Katherine R.
    Wang, Shan
    Hastings, Andrew K.
    Youngblood, Victoria M.
    Santapuram, Pranav R.
    Chen, Haiying
    Cates, Justin M.
    Colvin, Daniel C.
    Ye, Fei
    Brantley-Sieders, Dana M.
    Cook, Rebecca S.
    Tan, Li
    Gray, Nathanael S.
    Chen, Jin
    [J]. JOURNAL OF CLINICAL INVESTIGATION, 2014, 124 (05) : 2037 - 2049
  • [3] Discovery and structural analysis of Eph receptor tyrosine kinase inhibitors
    Choi, Yongmun
    Syeda, Farisa
    Walker, John R.
    Finerty, Patrick J., Jr.
    Cuerrier, Dominic
    Wojciechowski, Amy
    Liu, Qingsong
    Dhe-Paganon, Sirano
    Gray, Nathanael S.
    [J]. BIOORGANIC & MEDICINAL CHEMISTRY LETTERS, 2009, 19 (15) : 4467 - 4470
  • [4] Mechanisms of ephrin-Eph signalling in development, physiology and disease
    Kania, Artur
    Klein, Ruediger
    [J]. NATURE REVIEWS MOLECULAR CELL BIOLOGY, 2016, 17 (04) : 240 - 256
  • [5] EphA2 Mediates Ligand-Dependent Inhibition and Ligand-Independent Promotion of Cell Migration and Invasion via a Reciprocal Regulatory Loop with Akt
    Miao, Hui
    Li, Da-Qiang
    Mukherjee, Amitava
    Guo, Hong
    Petty, Aaron
    Cutter, Jennifer
    Basilion, James P.
    Sedor, John
    Wu, Jiong
    Danielpour, David
    Sloan, Andrew E.
    Cohen, Mark L.
    Wang, Bingcheng
    [J]. CANCER CELL, 2009, 16 (01) : 9 - 20
  • [6] AKT as a Therapeutic Target for Cancer
    Song, Mengqiu
    Bode, Ann M.
    Dong, Zigang
    Lee, Mee-Hyun
    [J]. CANCER RESEARCH, 2019, 79 (06) : 1019 - 1031
  • [7] Hepatocellular Carcinoma
    Villanueva, Augusto
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 2019, 380 (15) : 1450 - 1462
  • [8] Targeting EphA2 suppresses hepatocellular carcinoma initiation and progression by dual inhibition of JAK1/STAT3 and AKT signaling
    Wang, Hao
    Hou, Wei
    Perera, Aldeb
    Bettler, Carlee
    Beach, Jordan R.
    Ding, Xianzhong
    Li, Jun
    Denning, Mitchell F.
    Dhanarajan, Asha
    Cotler, Scott J.
    Joyce, Cara
    Yin, Jun
    Ahmed, Fowsiyo
    Roberts, Lewis R.
    Qiu, Wei
    [J]. CELL REPORTS, 2021, 34 (08):
  • [9] The EphA2 Receptor and EphrinA1 Ligand in Solid Tumors: Function and Therapeutic Targeting
    Wykosky, Jill
    Debinski, Waldemar
    [J]. MOLECULAR CANCER RESEARCH, 2008, 6 (12) : 1795 - 1806
  • [10] Revisiting STAT3 signalling in cancer: new and unexpected biological functions
    Yu, Hua
    Lee, Heehyoung
    Herrmann, Andreas
    Buettner, Ralf
    Jove, Richard
    [J]. NATURE REVIEWS CANCER, 2014, 14 (11) : 736 - 746
1